Blog
Streamlining IRB review process for multi-site research
On 6/21/16, the National Institutes of Health (NIH) issued a final policy to streamline IRB review. Expectations are that a single IRB (sIRB) will be used for all non-exempt multi-site research at U.S. sites for research funded by NIH. There may be exceptions only if...
Pearl Pathways’ own Diana Caldwell completes Goldman Sachs 10,000 Small Businesses
Pearl Pathways is proud to announce that its President and CEO, Diana Caldwell recently completed an elite entrepreneurship training program in the Babson College Cohort of Goldman Sachs’ 10,000 Small Business program. She is among 137 entrepreneurs who graduated in...
Empowered Patients in Clinical Trials
Reading an article by Ed Miseta, Clinical Leader, brought to mind the importance of the balance of patient’s needs and scientific advancement. Miseta’s article shared comments from leaders in Pharma where empowered patients and their community voice is recognized and...
Latest updates on Compassionate Use
The FDA has been working to improve the process used by physicians to request Expanded Access -- Compassionate Use to investigational drugs and biologics for their patients who need these therapies to stay alive. In a statement released in early June from FDA...
Save the date: 2nd Annual Cell Therapy and Regenerative Medicine Symposium held in Indianapolis 6/13
Pearl Pathways will again be sponsoring the 2nd Annual Cell Therapy and Regenerative Medicine Symposium to be held June 13, 2016 in Indianapolis, Indiana. The theme is commercialization and the title of this year's program is "Commercialization and Health Care System...